X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (114) 114
low-dose naltrexone (103) 103
humans (93) 93
animals (69) 69
naltrexone (68) 68
male (50) 50
pharmacology & pharmacy (50) 50
neurosciences (46) 46
female (43) 43
dose-response relationship, drug (35) 35
pain (31) 31
naltrexone - administration & dosage (30) 30
care and treatment (29) 29
double-blind (29) 29
mice (28) 28
morphine (25) 25
multiple sclerosis (22) 22
naloxone (22) 22
narcotic antagonists - pharmacology (22) 22
adult (21) 21
fibromyalgia (21) 21
quality-of-life (21) 21
analgesia (20) 20
narcotic antagonists - administration & dosage (20) 20
opioids (20) 20
rats (20) 20
analysis (19) 19
middle aged (19) 19
dependence (18) 18
clinical neurology (17) 17
low dose naltrexone (17) 17
naltrexone - pharmacology (17) 17
narcotic antagonists - therapeutic use (17) 17
dosage and administration (16) 16
neurology (16) 16
article (15) 15
naltrexone - therapeutic use (15) 15
opioid growth factor (15) 15
clinical trials (14) 14
drug therapy (14) 14
psychiatry (14) 14
antinociceptive potency (13) 13
biochemistry & molecular biology (13) 13
health aspects (13) 13
multiple-sclerosis (13) 13
narcotics (13) 13
therapy (13) 13
treatment outcome (13) 13
beta-endorphin (12) 12
drug synergism (12) 12
immunology (12) 12
medicine & public health (12) 12
medicine, research & experimental (12) 12
opioid receptors (12) 12
placebo-controlled trial (12) 12
sensory neurons (12) 12
aged (11) 11
analgesics, opioid - pharmacology (11) 11
cancer (11) 11
chronic pain (11) 11
cytokines (11) 11
drug dosages (11) 11
medicine, general & internal (11) 11
neuropathic pain (11) 11
studies (11) 11
substance abuse (11) 11
anesthesiology (10) 10
behavioral sciences (10) 10
disease models, animal (10) 10
drugs (10) 10
experimental autoimmune encephalomyelitis (10) 10
pharmacology (10) 10
pharmacotherapy (10) 10
receptors, opioid - metabolism (10) 10
research (10) 10
review (10) 10
rodents (10) 10
spinal-cord (10) 10
tolerance (10) 10
abridged index medicus (9) 9
brain (9) 9
controlled-trial (9) 9
encephalomyelitis, autoimmune, experimental - pathology (9) 9
inflammation (9) 9
internal medicine (9) 9
ldn (9) 9
medicine (9) 9
mice, inbred c57bl (9) 9
morphine - pharmacology (9) 9
opioid growth-factor (9) 9
patients (9) 9
proliferation (9) 9
receptors (9) 9
addiction (8) 8
alcohol (8) 8
analgesics, opioid - adverse effects (8) 8
cell proliferation (8) 8
disease (8) 8
drug administration schedule (8) 8
drug interactions (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 06/2019, Volume 80, Issue 6, pp. 1746 - 1752
Naltrexone in standard and reduced doses is efficacious in many inflammatory and acantholytic disorders. We summarized the current data of naltrexone that are... 
opioid receptor | opioid receptor antagonist | pruritus | naltrexone | dermatology | low-dose naltrexone | psoriasis | scleroderma | Hailey–Hailey disease | lichen planopilaris | opioids | NERVE-ENDINGS | SAFETY | OPIOID GROWTH-FACTOR | Hailey-Hailey disease | DNA-SYNTHESIS | MU-OPIATE RECEPTOR | HUMAN KERATINOCYTES | MULTIPLE-SCLEROSIS | SKIN | EXPRESSION
Journal Article
Pain Medicine, ISSN 1526-2375, 05/2009, Volume 10, Issue 4, pp. 663 - 672
Journal Article
Biological Psychiatry, ISSN 0006-3223, 2012, Volume 72, Issue 10, pp. 832 - 838
Journal Article
The American Journal of Drug and Alcohol Abuse, ISSN 0095-2990, 11/2018, Volume 44, Issue 6, pp. 619 - 627
Background: There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic... 
treatment | Cannabis | marijuana | medication | pilot | CONTROLLED-TRIAL | N-ACETYLCYSTEINE | USE DISORDER | SUBSTANCE ABUSE | RELEASE | PSYCHOLOGY, CLINICAL | THC | OPIOID ANTAGONISM | LOW DOSE NALTREXONE | DOUBLE-BLIND | DELTA-TETRAHYDROCANNABINOL | Drug abuse | Drug dependency | Critical incidents | Clinical trials | Clinical research | Efficacy | Naltrexone | Dosage | Studies | Marijuana | Feasibility | Drug therapy | Substance abuse disorders
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 03/2018, Volume 38, Issue 3, pp. 382 - 389
Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Due to the difficulty of treating these diseases and the... 
antiinflammatory agents | naltrexone | chronic pain | fibromyalgia | multiple sclerosis | analgesia | low‐dose naltrexone | Crohn's disease | low-dose naltrexone | UNITED-STATES | OPIOID GROWTH-FACTOR | PREVALENCE | MODEL | FACTOR OGF | FACTOR RECEPTOR | PILOT TRIAL | NEUROPATHIC PAIN | LDN | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | Narcotic Antagonists - administration & dosage | Humans | Dose-Response Relationship, Drug | Multiple Sclerosis - physiopathology | Naltrexone - pharmacology | Anti-Inflammatory Agents - adverse effects | Inflammation - drug therapy | Fibromyalgia - drug therapy | Anti-Inflammatory Agents - administration & dosage | Chronic Pain - etiology | Naltrexone - administration & dosage | Chronic Pain - drug therapy | Anti-Inflammatory Agents - pharmacology | Narcotic Antagonists - adverse effects | Inflammation - etiology | Animals | Crohn Disease - drug therapy | Narcotic Antagonists - pharmacology | Quality of Life | Crohn Disease - physiopathology | Chronic Pain - physiopathology | Fibromyalgia - physiopathology | Naltrexone - adverse effects | Inflammation - physiopathology | Multiple Sclerosis - drug therapy | Medical research | Care and treatment | Multiple sclerosis | Pain | Alternative medicine | Medicine, Experimental | Fibromyalgia | Dosage and administration | Inflammation | B cells | Naltrexone | Chronic pain | Cell proliferation | Inflammatory bowel diseases | Effectiveness | Narcotics | Clinical trials | Opioid receptors (type mu) | Patients | Inflammatory diseases | Quality of life | Diseases | Crohns disease | Alcohols | Lymphocytes B | Toll-like receptors | Safety | Drug dependence
Journal Article
EXPERIMENTAL BIOLOGY AND MEDICINE, ISSN 1535-3702, 09/2017, Volume 242, Issue 15, pp. 1524 - 1533
Low-dose naltrexone is a widely used off-label therapeutic prescribed for a variety of immune-related disorders. The mechanism underlying low-dose naltrexone's... 
MEDICINE, RESEARCH & EXPERIMENTAL | beta-endorphin | opioid growth factor | FACTOR RECEPTOR AXIS | OPIOID GROWTH-FACTOR | CELL-PROLIFERATION | PILOT TRIAL | Low-dose naltrexone | experimental autoimmune encephalomyelitis | [Met]-enkephalin | PATHWAY | QUALITY-OF-LIFE | BLOCKADE | DURATION | ELISA
Journal Article
Journal of Cutaneous Medicine and Surgery, ISSN 1203-4754, 7/2019, Volume 23, Issue 4, pp. 453 - 454
Journal Article
Medical sciences (Basel, Switzerland), ISSN 2076-3271, 09/2018, Volume 6, Issue 4, p. 82
Naltrexone and naloxone are classical opioid antagonists. In substantially lower than standard doses, they exert different pharmacodynamics. Low-dose... 
naltrexone | pain | low-dose naltrexone | fibromyalgia | naloxone | glia | Crohn’s disease
Journal Article
Journal Article
15.